Fierce Pharma

ESMO: Keytruda, Padcev reduce risk of death by 50% in another massive showing in bladder cancer

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...
The American Journal of Managed Care

Enfortumab Vedotin Plus Pembro Boosts Survival in Key Groups With Bladder Cancer Before and After Surgery, Phase 3 Study Finds

Enfortumab vedotin plus pembrolizumab significantly improves EFS and OS in cisplatin-ineligible MIBC patients, offering a new treatment option. The EV-303 trial is the first to show systemic treatment ...

Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients

(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor ...

Blood test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...
Business Wire

Virtuoso Surgical Robotic System Used To Perform Successful First-in-Human Bladder Cancer Removal Cases: Enables Cutting Edge Surgical Approach

NASHVILLE, Tenn.--(BUSINESS WIRE)--Virtuoso Surgical Inc., a Nashville-based surgical robotics company, today announced the first-in-human use of its Virtuoso system, ushering in a new era of ...